天津武清区龙济泌尿专科要预约吗(白庙客运站与天津武清龙济男科医院近吗) (今日更新中)

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The Republican Party announced tonight that President Donald Trump will accept the GOP nomination for president in Jacksonville, Florida. The convention was originally planned for Charlotte, North Carolina.The party could not receive assurances from North Carolina's Democratic governor that a ban on mass gatherings would not be lifted in time for the convention. North Carolina, like a number of other states, have limited mass public gathering during the spread of COVID-19.“We are thrilled to hold @realDonaldTrump 's acceptance of the Republican nomination in the great city of Jacksonville!” GOP chairperson Ronna McDaniel tweeted. “Not only is Florida his home state, it is crucial to victory. We look forward to bringing this great celebration and economic boon to the Sunshine State!”The party said it will still hold a number of convention-related activities in Charlotte."Because the current North Carolina COVID-19 restrictions would not allow for the celebration to occur in Charlotte and Governor [Roy] Cooper would not work with the RNC to offer guidelines, the celebration of the nomination and the economic impact that goes with it must be moved to Jacksonville," the GOP said in a statement.Despite a rise in coronavirus cases in recent weeks in Florida, the state's Republican governor was eager to accept the relocated nomination."Florida is honored to host this special event where we will celebrate the re-nomination of President Donald J. Trump," said Florida Governor Ron DeSantis. "Jacksonville is a great city that will showcase Florida’s energy, facilities, entrepreneurship and commitment to bring together the delegates of the Republican Party at a historic time in our nation’s history." 1726

The Ventura County Medical Examiner has ruled "Glee" star Naya Rivera's cause of death as an accidental drowning.Rivera's body was recovered from Lake Piru in Ventura County on Monday. On Tuesday, the medical examiner was able to confirm through dental comparison that the body recovered was Rivera's, according to a statement from the medical examiner. 361

The Sanderson Sisters from "Hocus Pocus" are back and ready to put a spell on you this Halloween.Bette Midler, Sarah Jessica Parker, and Kathy Najimy are reuniting as The Sanderson Sisters from the cult classic "Hocus Pocus." The sisters will be treating us to a virtual event on Oct. 30. And it's all for a good cause.According to the New York Restoration Project (NYRP) website, tickets for the "In Search of the Sanderson Sisters: A Hocus Pocus Hulaween Takeover" are .All the money raised will benefit the nonprofit NYRP, which Midler started in 1995. They restore parks and plant trees in New York City.Midler tweeted a picture of all three actresses together as Winifred, Mary, and Sarah Sanderson. 715

The Supreme Court on Tuesday rejected a challenge to a controversial Arkansas abortion law blocking medication-induced abortions.The law, passed in 2015, says that any physician who "gives, sells, dispenses, administers, or otherwise provides or proscribes the abortion-inducing drug" shall have to have a contract with a physician who has admitting privileges at a nearby hospital.The order, issued without comment, clears the way for the law to go into effect in mid-July if no other legal action is taken. Planned Parenthood is expected to make another challenge to the law in US district court."The Arkansas restriction, which was enacted supposedly to protect women's health, is medically unnecessary," lawyers for Planned Parenthood argued in court papers. They say it is unconstitutional because it places an undue burden on a patient's right to choose abortion.Medication abortion — available only early in a pregnancy — involves the combination of two pills called mifepristone and misoprostol.Lawyers for Arkansas say the law is a "commonsense requirement" that "merely requires medication abortion providers to have a contractual relationship (to ensure follow-up treatment if needed) with a physician that has admitting privileges.The-CNN-Wire 1263

来源：资阳报